Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013 (2013), Article ID 429545, 10 pages
http://dx.doi.org/10.1155/2013/429545
Research Article

Effect of Vasoactive Intestinal Peptide (VIP) on NKG2D Signal Pathway and Its Contribution to Immune Escape of MKN45 Cells

Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China

Received 24 June 2013; Accepted 13 August 2013

Academic Editors: T. Hida and K. Higai

Copyright © 2013 Chong Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Caligiuri, “Human natural killer cells,” Blood, vol. 112, no. 3, pp. 461–469, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. A. M. Jamieson, A. Diefenbach, C. W. McMahon, N. Xiong, J. R. Carlyle, and D. H. Raulet, “The role of the NKG2D immunoreceptor in immune cell activation and natural killing,” Immunity, vol. 17, no. 1, pp. 19–29, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Guerra, Y. X. Tan, N. T. Joncker et al., “NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy,” Immunity, vol. 28, no. 4, pp. 571–580, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. D. D. Billadeau, J. L. Upshaw, R. A. Schoon, C. J. Dick, and P. J. Leibson, “NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway,” Nature Immunology, vol. 4, no. 6, pp. 557–564, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Garrity, M. E. Call, J. Feng, and K. W. Wucherpfennig, “The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 21, pp. 7641–7646, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Fukumoto, M. Ikeguchi, S. Matsumoto et al., “Detection of cancer cells and gene expression of cytokines in the peritoneal cavity in patients with gastric cancer,” Gastric Cancer, vol. 9, no. 4, pp. 271–276, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. S. I. Said and V. Mutt, “Polypeptide with broad biological activity: isolation from small intestine,” Science, vol. 169, no. 3951, pp. 1217–1218, 1970. View at Google Scholar · View at Scopus
  8. M. Delgado and D. Ganea, “Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions,” Amino Acids, vol. 45, no. 1, pp. 25–39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Valdehita, M. J. Carmena, A. M. Bajo, and J. C. Prieto, “RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells,” Molecular and Cellular Endocrinology, vol. 348, no. 1, pp. 241–246, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. G. H. Li, W. Qian, G. Q. Song, and X. H. Hou, “Effect of vasoactive intestinal peptide on gastric adenocarcinoma,” Journal of Gastroenterology and Hepatology, vol. 22, no. 8, pp. 1328–1335, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Langer and P. Robberecht, “Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors,” Biochemical Society Transactions, vol. 35, part 4, pp. 724–728, 2007. View at Google Scholar · View at Scopus
  12. S. Schulz, C. Röcken, C. Mawrin, W. Weise, V. Höllt, and S. Schulz, “Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies,” Clinical Cancer Research, vol. 10, no. 24, pp. 8235–8242, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. S. S. Diebold, “Activation of dendritic cells by toll-like receptors and C-type lectins,” in Handbook of Experimental Pharmacology, vol. 188, pp. 3–30, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Chorny, E. Gonzalez-Rey, A. Fernandez-Martin, D. Pozo, D. Ganea, and M. Delgado, “Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 38, pp. 13562–13567, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. E. J. Goetzl, R. C. Chan, and M. Yadav, “Diverse mechanisms and consequences of immunoadoption of neuromediator systems,” Annals of the New York Academy of Sciences, vol. 1144, pp. 56–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Lv, Y. Tang, F. Chen, and X. Xiao, “Vasoactive intestinal peptide and pituary adenylate cyclase-activating polypeptide inhibit tissue factor expression in monocyte in vitro and in vivo,” Shock, vol. 31, no. 2, pp. 185–191, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. E. A. Szliter, S. Lighvani, R. P. Barrett, and L. D. Hazlett, “Vasoactive intestinal peptide balances pro- and anti-inflammatory cytokines in the Pseudomonas aeruginosa-infected cornea and protects against corneal perforation,” Journal of Immunology, vol. 178, no. 2, pp. 1105–1114, 2007. View at Google Scholar · View at Scopus
  18. M. Hejna, G. Hamilton, T. Brodowicz et al., “Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract,” Anticancer Research, vol. 21, no. 2, pp. 1183–1188, 2001. View at Google Scholar · View at Scopus
  19. E. Ciccone, D. Pende, O. Viale et al., “Specific recognition of human CD3-CD16+ natural killer cells requires the expression of an autosomic recessive gene on target cells,” Journal of Experimental Medicine, vol. 172, no. 1, pp. 47–52, 1990. View at Publisher · View at Google Scholar · View at Scopus
  20. M. A. Tzaneva, “Endocrine cells in gastric carcinoma and adjacent mucosa. An immunohistochemical and ultrastructural study,” Histochemical Journal, vol. 34, no. 3-4, pp. 173–180, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Yadav and E. J. Goetzl, “Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity,” Annals of the New York Academy of Sciences, vol. 1144, pp. 83–89, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Champsaur and L. L. Lanier, “Effect of NKG2D ligand expression on host immune responses,” Immunological Reviews, vol. 235, no. 1, pp. 267–285, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. D. H. Raulet, “Roles of the NKG2D immunoreceptor and its ligands,” Nature Reviews Immunology, vol. 3, no. 10, pp. 781–790, 2003. View at Google Scholar · View at Scopus
  24. B. Zafirova, F. M. Wensveen, M. Gulin, and B. Polić, “Regulation of immune cell function and differentiation by the NKG2D receptor,” Cellular and Molecular Life Sciences, vol. 68, no. 21, pp. 3519–3529, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. C. M. Tato, N. Mason, D. Artis et al., “Opposing roles of NF-κB family members in the regulation of NK cell proliferation and production of IFN-γ,” International Immunology, vol. 18, no. 4, pp. 505–513, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Wan and M. J. Lenardo, “The nuclear signaling of NF-κB: current knowledge, new insights, and future perspectives,” Cell Research, vol. 20, no. 1, pp. 24–33, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Nakashima, M. Deie, S. Yanada, P. Sharman, and M. Ochi, “Magnetically labeled human natural killer cells, accumulated in vitro by an external magnetic force, are effective against HOS osteosarcoma cells,” International Journal of Oncology, vol. 27, no. 4, pp. 965–971, 2005. View at Google Scholar · View at Scopus
  28. A. Piroozmand and Z. M. Hassan, “Evaluation of natural killer cell activity in pre and post treated breast cancer patients,” Journal of Cancer Research and Therapeutics, vol. 6, no. 4, pp. 478–481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Yoshida, J. Nakajima, H. Wada, and K. Kakimi, “γδ T-cell immunotherapy for lung cancer,” Surgery Today, vol. 41, no. 5, pp. 606–611, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Maasho, J. Opoku-Anane, A. I. Marusina, J. E. Coligan, and F. Borrego, “Cutting edge: NKG2D is a costimulatory receptor for human naive CD8+ T cells,” Journal of Immunology, vol. 174, no. 8, pp. 4480–4484, 2005. View at Google Scholar · View at Scopus
  31. M. Girardi, D. E. Oppenheim, C. R. Steele et al., “Regulation of cutaneous malignancy by γδ T cells,” Science, vol. 294, no. 5542, pp. 605–609, 2001. View at Publisher · View at Google Scholar · View at Scopus